Your browser doesn't support javascript.
loading
Association Between Germline Mutations in BRF1, a Subunit of the RNA Polymerase III Transcription Complex, and Hereditary Colorectal Cancer.
Bellido, Fernando; Sowada, Nadine; Mur, Pilar; Lázaro, Conxi; Pons, Tirso; Valdés-Mas, Rafael; Pineda, Marta; Aiza, Gemma; Iglesias, Silvia; Soto, José Luís; Urioste, Miguel; Caldés, Trinidad; Balbín, Milagros; Blay, Pilar; Rueda, Daniel; Durán, Mercedes; Valencia, Alfonso; Moreno, Victor; Brunet, Joan; Blanco, Ignacio; Navarro, Matilde; Calin, George A; Borck, Guntram; Puente, Xose S; Capellá, Gabriel; Valle, Laura.
Afiliação
  • Bellido F; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL and CIBERONC, Hospitalet de Llobregat, Barcelona, Spain.
  • Sowada N; Institute of Human Genetics, University of Ulm, Ulm, Germany.
  • Mur P; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL and CIBERONC, Hospitalet de Llobregat, Barcelona, Spain.
  • Lázaro C; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL and CIBERONC, Hospitalet de Llobregat, Barcelona, Spain.
  • Pons T; Structural Biology and Biocomputing Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
  • Valdés-Mas R; Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo, Oviedo, Spain.
  • Pineda M; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL and CIBERONC, Hospitalet de Llobregat, Barcelona, Spain.
  • Aiza G; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL and CIBERONC, Hospitalet de Llobregat, Barcelona, Spain.
  • Iglesias S; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL and CIBERONC, Hospitalet de Llobregat, Barcelona, Spain.
  • Soto JL; Molecular Genetics Laboratory, Elche University Hospital, Elche, Spain; Alicante Institute for Health and Biomedical Research (ISABIAL-FISABIO Foundation), Alicante, Spain.
  • Urioste M; Familial Cancer Clinical Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO) and Center for Biomedical Network Research on Rare Diseases, Madrid, Spain.
  • Caldés T; Laboratorio de Oncología Molecular, Servicio de Oncología Médica, Hospital Clínico San Carlos, Madrid, Spain.
  • Balbín M; Laboratorio de Oncología Molecular, Instituto Universitario de Oncología del Principado de Asturias, Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Blay P; Familial Cancer Unit, Department of Medical Oncology, Instituto Universitario de Oncología del Principado de Asturias, Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Rueda D; Molecular Biology Laboratory, 12 de Octubre University Hospital, Madrid, Spain.
  • Durán M; Instituto de Biología y Genética Molecular, IBGM-UVA-CSIC, Valladolid, Spain.
  • Valencia A; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain; Life Science Department, Barcelona; Supercomputing Centre (BSC-CNS), Barcelona, Spain.
  • Moreno V; Unit of Biomarkers and Susceptibility, Catalan Institute of Oncology, IDIBELL and CIBERESP, Hospitalet de Llobregat, Spain; Department of Clinical Sciences, School of Medicine, University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain.
  • Brunet J; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL and CIBERONC, Hospitalet de Llobregat, Barcelona, Spain; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBGi, Girona, Spain.
  • Blanco I; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL and CIBERONC, Hospitalet de Llobregat, Barcelona, Spain.
  • Navarro M; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL and CIBERONC, Hospitalet de Llobregat, Barcelona, Spain.
  • Calin GA; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Borck G; Institute of Human Genetics, University of Ulm, Ulm, Germany.
  • Puente XS; Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo, Oviedo, Spain.
  • Capellá G; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL and CIBERONC, Hospitalet de Llobregat, Barcelona, Spain.
  • Valle L; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL and CIBERONC, Hospitalet de Llobregat, Barcelona, Spain. Electronic address: lvalle@iconcologia.net.
Gastroenterology ; 154(1): 181-194.e20, 2018 01.
Article em En | MEDLINE | ID: mdl-28912018
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Mutação em Linhagem Germinativa / Fatores Associados à Proteína de Ligação a TATA País/Região como assunto: Europa Idioma: En Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Espanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Mutação em Linhagem Germinativa / Fatores Associados à Proteína de Ligação a TATA País/Região como assunto: Europa Idioma: En Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Espanha